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Abstract 
Aim: Prophylactic probiotics to reduce necrotising enterocolitis (NEC) are mostly given for at 
least 28 days or until discharge. We describe the effects of a shorter duration dosing 
strategy. 
Methods: Retrospective cohort study of neonates (birth weight 400-1,500 g) in three 
neonatal intensive care units in Switzerland and Germany that embarked on probiotic 
prophylaxis given for 10 or 14 days, employing a fixed combination (Lactobacillus 
acidophilus plus Bifidobacterium infantis, each 109 CFU/d) licensed as a drug in Switzerland. 
Probiotics were initiated upon discontinuation of antibiotics, or on day 1-3 in infants without 
antibiotics. Repeat probiotic courses were given whenever antibiotics had been instituted 
and were discontinued. 
Results: Birth weight and gestational age were similar in the two 24-month pre- and post-
implementation cohorts. NEC rates fell from 33/633 (5.2%) to 8/591 infants alive at 3 days 
(1.4%; risk ratio (RR) 0.26, 95% confidence interval (CI) 0.12-0.55). The drop in NEC was 
significant both for infants of 400-999 g (6.4% to 2.5%) and 1,000-1,500 g birth weight (4.4% 
to 0.6%). Mortality was 5.1% (32/633) without, as opposed to 3.5% (21/591) with probiotics, 
respectively (RR 0.69, 95% CI 0.41-1.19). 
Conclusion: Short courses of a dual-strain probiotics appear to be effective in reducing 
NEC. 
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Key notes 
• The risk of necrotising enterocolitis decreases with the use of prophylactic 
probiotics but the optimal duration is unknown. 
• In most trials, prophylactic probiotics were given over prolonged periods of time, 
sometimes until discharge.  
• In our study, dual-strain probiotics consisting of Lactobacillus acidophilus and 
Bifidobacterium infantis were highly effective in reducing rates of necrotising 
enterocolitis when given for 10-14 days, with repeat courses after any institution of 
antibiotics. 
 
Introduction  
Initial colonisation of the neonatal intestinal tract has short and long-term 
consequences, as some bacteria play important roles in regulating mucosal immunity and 
establishing barrier formation, whereas others may cause inflammatory disease. Alterations 
of gut bacterial colonisation observed in preterm, as compared to term infants, are 
aggravated by exposure to antibiotics before and after delivery. Antibiotics have been shown 
to affect the composition of intestinal microbiota for up to 90 days, decreasing abundance of 
bifidobacteria while increasing enterobacteriaceae (1). Such shifts in microbial composition 
may turn into intestinal dysbiosis that contributes to the development of necrotising 
enterocolitis (NEC) (2-5). Both prenatal (6, 7) and postnatal antibiotics (8-10) have been 
found to be associated with NEC in very low birth weight (< 1,500 g, VLBW) infants.  
Probiotics can be viewed as an attempt to correct for the side effects of perinatal 
antibiotics in preterm infants and appear to counteract their NEC promoting effects. Meta-
analyses of randomised controlled trials suggest that prophylactic administration of 
probiotics reduces the rates of NEC and all-cause mortality in VLBW infants (11), and 
introduction of routine administration of probiotics is associated with a decline in the 
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incidence of NEC (12-16). Various clinicians and investigators, however, have voiced 
concerns, as probiotic bacteria used as NEC prophylaxis have been isolated in blood 
cultures of sick very low birth weight infants (17-19). Moreover, the most effective probiotic 
or combination of probiotics, dosage and timing are unknown (20). A comparison of the 
results of randomised controlled trials using probiotics containing combinations of two or 
more bacterial species with trials employing single-strain probiotics suggests that 
combination probiotics are more effective than single-strain probiotics in reducing rates of 
NEC and mortality (11). The optimal duration of probiotics administration remains an open 
question.  
After the results of the first two single randomised controlled trials that demonstrated 
a significant reduction of NEC and mortality in VLBW infants with the use of prophylactic 
multiple-strain probiotics became known (21, 22), three tertiary care neonatal intensive care 
units of the university hospitals of Zürich (Switzerland) and Berlin (Germany) sequentially 
embarked on an institutional policy to prescribe probiotics combining Lactobacillus 
acidophilus and Bifidobacterium infantis licensed by the Federal Swiss Agency for 
Therapeutic Products (Swissmedic) for use in infants (Infloran). In contrast to schemes 
employed elsewhere, the institutional guidelines called for the probiotics to be administered 
only for 10 or 14 days, with repeat courses after a second or third round of antibiotics for 
suspected or proven nosocomial infection. The short exposure time, as compared to those of 
the protocols of the randomised controlled trials, was chosen as intestinal colonisation with 
probiotic strains appears to persist at least two weeks after cessation of probiotic 
administration (23). There were also concerns about the concomitant administration of 
probiotics and broad-spectrum antibiotics (24). Here, we report NEC and mortality rates 
before and after introduction of this abbreviated scheme of prophylactic dual-strain probiotics 
administration. 
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Patients and methods 
The routine use of probiotics for VLBW infants was started in September 2007 
(University Hospital Zürich), in July 2008 (Charité Berlin, Campus East) and in November 
2008 (Charité Berlin, Campus West). VLBW infants received ½ capsule of Infloran 
(Laboratorio Farmaceutico, Mede, Italy) containing Lactobacillus acidophilus (1x109 CFU) 
and Bifidobacterium infantis (1x109 CFU) twice daily (total daily dose 1x109 CFU of each 
organism) for 10 (Berlin) or 14 (Zürich) consecutive days. Probiotics were started on day 1 
(Zürich) to 3 (Berlin) of life in infants who had not been put on antibiotics at admission. In 
infants given antibiotics upon admission, probiotic prophylaxis was started on the very day 
antibiotics were discontinued. Probiotic prophylaxis was repeated (again for 10 or 14 days, 
respectively) after further rounds of antibiotics as long as infants had an actual body weight 
below 1,500 g or an actual corrected gestational age below 32 weeks.   
The feeding regimen of the three units similarly called for maternal milk started within 
the first 24 hours of life. If maternal milk was unavailable, infants received donor milk in 
Berlin unless the mother objected, while they received preterm formula in Zürich.  
In this analysis, we used the anonymised quality control data sets (25) to compare 
rates of mortality and NEC stage 2 or more in VLBW infants who had survived for at least 
72 hours between two 24-month periods (before and 6 months after introduction of probiotic 
prophylaxis, respectively). The study was approved by the two local institutional review 
boards (KEK-ZH-Nr 2014-0512, EA2/130/14).  
Groups were compared by the Mann Whitney U, chi square test or two-tailed Fisher’s 
exact test, using Statgraphics Plus 5.0; (Statistical Graphics Corp., Warrenton, Virginia, 
USA). Risk ratios (RR) with 95% confidence intervals (CI) (Mantel and Haenszel) and 
heterogeneity (Higgins) were calculated using the software Review Manager (RevMan 5.1.2; 
The Cochrane Collaboration, London, England). Fixed analyses were calculated after 
heterogeneity between the three NICUs was found to be low.  
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Results 
In the two 24-month periods before and after routine use of probiotic prophylaxis, the 
three tertiary care NICUs admitted 700 and 652 infants, of whom 67 and 61 infants, 
respectively, died within the first 72 hours of life (p=0.926). Patients’ characteristics of infants 
alive at 72 hours and therefore included in the analysis were similar for the two periods 
(Table 1). The incidence of NEC (≥ stage 2) decreased from 5.2% (33/633) to 1.4% (8/591), 
translating into a risk RR of 0.26 (95% CI 0.12-0.55). The reduction in NEC was significant 
for the strata of infants with a birth weight of 400-999 g and 1,000-1,500 g, being somewhat 
more pronounced in infants with a birth weight ≥ 1,000 g (Table 2). Rates of mortality did not 
differ significantly between the two time periods (5.1% vs 3.6%). There was no change in 
survivors with respect to the rates of retinopathy of prematurity ≥ stage 2 (10.3%, 62/601, vs 
12.3%, 70/570) or chronic lung disease, as defined by oxygen requirement at 36 weeks 
gestational age (9.8%, 59/601, vs 8.9%, 51/570). 
 
Discussion 
This retrospective cohort study suggests that 10 or 14-day courses of probiotics 
started immediately after elective cessation of antibiotics are as effective in reducing the 
rates of NEC in preterm infants with a birth weight < 1,500 g as continuous administration of 
probiotics for prolonged periods of time. The RR of NEC for infants < 1,500 g birth weight 
associated with the use of a short course of probiotics (0.26, 95% CI 0.12-0.55) was similar 
to that of the most recent meta-analysis (11) of all published randomised controlled trials 
(0.41, 95% CI 0.31-0.56) or randomised controlled trials using multiple-strain probiotics 
(0.37, 95% CI 0.25-0.54). The comparison of the pre-implementation and post-
implementation cohorts failed to demonstrate a significant reduction in mortality.  
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The reduced rates of NEC associated with the introduction of probiotics might have 
been linked to other changes in practice, a problem inherent to similar longitudinal studies 
(12-16). Other, yet unaccounted factors may have contributed to the reduced NEC rates 
observed, such as less antenatal antibiotics, more breastfeeding, or emphasis on late cord 
clamping. These practice parameters are not contained in the anonymised quality control 
data sets the analysis is based upon. The effect size, however, was similar for the units in 
Zürich and Berlin, despite the difference in duration of probiotics (14 days versus 10 days) 
and disparities in feeding regimens for infants whose mothers did not provide breast milk 
(preterm formula in Zürich, donor bank milk in Berlin). In both places, probiotics tended to 
influence NEC-related mortality (RR 0.27, 95% CI 0.06-1.26) but not mortality unrelated to 
NEC (RR 0.93, 95% CI 0.55-1.58). There was little variation in case mix between the pre- 
and post-implementation cohorts, as judged by birth weight and gestational age.  
 Probiotics consist of live bacteria differing in their efficacy to colonise various 
segments of the gut (26). It may be hypothesised that they multiply in the intestinal lumen 
unless killed by antibiotics (23), rendering it pointless to provide additional probiotic bacteria 
once colonisation is firmly established. The results of our analysis suggest that a short 
course (10-14 days) of probiotics consisting of Lactobacillus acidophilus and Bifidobacterium 
infantis may be sufficient to prevent NEC, provided further courses of probiotics are given to 
infants put on intravenous antibiotics for nosocomial infections. While the data set used for 
the analysis did not directly provide numbers to show how many infants had more than one 
course of probiotics, data from the neonatal nosocomial surveillance system (27) indicated 
that 20% of VLBW infants of the Berlin cohort 2009-2011 had any type of nosocomial 
infection beyond 3 days of life (including culture-negative suspected clinical sepsis), and 
0.8% had two such nosocomial infections. In the Zürich cohort, 7.7% of VLBW infants had 
one culture-positive nosocomial septicaemia, and 0.3% had two culture-positive 
septicaemias. This translates into about 19.3 % and 0.8% of VLBW infants, assuming that 
culture-positive septicaemias account for 40% of all nosocomial infections (27).  
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  Critics of trials employing probiotics to prevent NEC voiced their concerns that trials 
were conducted using probiotics marketed as dietary supplements that are not produced 
under stringent quality control and lack regulatory approval by national drug regulatory 
authorities. The probiotics employed in our units is a licensed drug in Switzerland for the use 
in infants (aimed at shortening the duration of diarrhoea). Its prescription to individual 
patients is covered by legislation in most European countries. While these probiotics were 
found to reduce rates of NEC and mortality in two large randomised controlled trials 
conducted in Taiwan (21, 28), it has been questioned whether these results would also apply 
to a central European setting (20). The data presented here reflect results of large neonatal 
intensive care units featuring NEC and mortality figures representative of Germany and 
Switzerland (25, 27).  
 
Conclusion 
The results of our study suggest that 10-14 day courses of dual-strain probiotics 
containing Lactobacilli and Bifidusbacteria, with repeat courses of probiotics after antibiotic 
administration, may be as efficient in reducing the rates of NEC as more prolonged 
administration of probiotics.  
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Table 1:                    Demographic data of the VLBW (400-1500 g) infants born in the three NICUs before and after introducing Infloran for 
routine use.  
 
_____________________________________________________________________________________________________________________________
__
 
  
  NICU: Zürich Berlin East Berlin West all 
 
 Probiotics: No Yes No Yes No Yes No Yes 
   ___________________________________________________________________________
 
 
Infants alive at 72 h (n)  220 217 151 156 262 218 633 591 
Sex male (n, %)  101 (46) 111 (51) 81 (54) 76 (49) 118 (45) 111 (51) 302 (48) 298 (50) 
 
Birth weight (g) 
 Mean 1116 1123 1054 1065 1069 1043 1082 1078 
 Median 1165 1150 1090 1075 1075 1070 1110 1100 
 Range 560-1500 530-1500 400-1490 480-1490 407-1495 439-1495 400-1500 439-1500 
 IQR 900-1330 880-1350 850-1280 840-1330 860-1320 777-1300 880-1320 850-1330 
 < 500 g (n, %) 0 (0) 0 (0) 4 (2.7) 2 (1.3) 5 (1.9) 5 (2.3)  9 (1.4) 7 (1.2) 
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Gestational age (weeks) 
 Mean 29.7 29.6 28.9 28.9 28.8 28.8 29.1 29.1 
 Median 29.4 29.6 28.7 28.4 28.4 29.0 28.9 29.0 
 Range 24.6-36.3 24.9-37.1 23.3-34.6 23.3-37.1 22.9-40.0 23.5-37.5 22.9-40.0 23.3-37.5 
 IQR 27.6-31.6 27.9-31.3 27.0-30.9 27.1-30.3 26.4-30.9 26.5-30.9 27.1-31.0 27.1-31.1 
 
IQR – Interquartile range 
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Table 2:                              Effect of routine use of probiotics on NEC and mortality in all VLBW infants and in VLBW infants stratified by birth weight 
 
_____________________________________________________________________________________________________________
 
 
  No probiotics Probiotics RR (95% CI) p 
 
 
_____________________________________________________________________________________________________________
 
Birth weight 400-1500 g 
Infants (n) 633 591   
Birth weight (g) 1110 (880-1320)  1100 (850-1330)  > 0.1 
Gestational age (weeks) 28.9 (27.1-31.0) 29 (27.1-31.1)  > 0.1 
NEC (n, %) 33 (5.2) 8 (1.4) 0.26 (0.12-0.55) 0.0005 
Mortality (n, %) 32 (5.1) 21 (3.6) 0.69 (0.41-1.19) >0.1 
NEC mortality (n, %) 8 (1.3) 2 (0.3) 0.27 (0.06-1.26) 0.07 
 
Birth weight 400-999 g 
Infants (n) 250 238   
Birth weight (g) 810 (660-930) 790 (680-885)  > 0.1 
Gestational age (weeks) 26.7 (25.3-28.3) 26.6 (25.4-28.1)  > 0.1 
NEC (n, %) 16 (6.4) 6 (2.5) 0.39 (0.16-0.99) 0.039 
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Mortality (n, %) 26 (10.4) 16 (6.7) 0.65 (0.36-1.17) > 0.1 
NEC mortality (n, %) 7 (2.8) 2 (0.84) 0.30 (0.06-1.43) > 0.1 
 
Birth weight 1000-1500 g 
Infants (n) 383 353   
Birth weight (g) 1270 (1150-1400) 1300 (1156-1410)  > 0.1 
Gestational age (weeks) 30.3 (28.7-31.7) 30.4 (29.0-32.0)  > 0.1 
NEC (n, %) 17 (4.4) 2 (0.57) 0.13 (0.03-0.55) 0.001 
Mortality (n, %) 6 (1.6) 5 (1.4) 0.90 (0.28-2.94) > 0.1 
NEC mortality (n, %) 1 (0.3) 0 (0) not estimable > 0.1 
 
 
Data for birth weight and gestational age are given as median and interquartile range 
 
